Edwards Lifesciences Says TAVR Superior to Surveillance in Moderate Aortic Stenosis Trial

01:25 PM EST, 11/02/2026 (MT Newswires) -- Edwards Lifesciences (EW) said Monday its Progress trial showed that proactive transcatheter aortic valve replacement, or TAVR, was superior to clinical surveillance in patients with moderate aortic stenosis. Data from the 744-patient trial showed TAVR delivered a 33% relative reduction in the primary composite endpoint of death or heart failure events at two years. Heart failure events occurred in 10.8% of patients receiving TAVR, compared with 19% under surveillance, while hospitalizations fell to 7.4% from 14.9%. Two-year all-cause mortality was similar between the groups. The trial also found that moderate aortic stenosis can progress faster than previously recognized, with 57% of patients in the surveillance group undergoing delayed valve replacement within two years. Before receiving treatment, these patients experienced declines in health status. Patients receiving TAVR also recorded a 15.5-point improvement in the Kansas City Cardiomyopathy Questionnaire, a quality-of-life assessment, at 30 days. Shares of Edwards Lifesciences were down nearly 4% in Monday trading. Price: 88.57, Change: -3.44, Percent Change: -3.74